Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Bi-Specific MAbS Market Growth in 2025?#_x000D_

The market size for bi-specific MAbS has experienced fast-paced growth in recent years. Predictions indicate it will escalate from $7.83 billion in 2024 to $9.1 billion in 2025, presenting a compound annual growth rate (CAGR) of 16.2%. The notable escalation in the past was a result of increased healthcare spending, augmented funding, and initiatives taken by the government._x000D_

_x000D_

#What Is the Forecast for the Bi-Specific MAbS Market Size Through 2029?#_x000D_

In the coming years, the bi-specific MAbS market is projected to experience a swift expansion. By 2029, it’s anticipated to reach a value of $15.19 billion, with a compound annual growth rate (CAGR) of 13.7%. This growth in the forecast period can be attributed to factors such as a rising prevalence of cancer, an aging population, and an increase in chronic disease incidence. Key trends during this period include an emphasis on technological advancements, innovation in products, the integration of artificial intelligence, investment in targeted and combination therapies, and the cultivation of strategic partnerships._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp_x000D_

_x000D_

#What are the Key Market Players in Bi-Specific MAbS Market and How They’re Evolving?#_x000D_

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa_x000D_

_x000D_

#What Are the Primary Growth Drivers in the Bi-Specific MAbS Market?#_x000D_

The surging occurrence of cancer and other long-lasting diseases is expected to fuel the expansion of the bispecific monoclonal antibodies market in the coming years. These antibodies are formulated for therapy options in multiple conditions like cancers, infectious diseases, disorders affecting the central nervous system, and autoimmune disorders. Bispecific monoclonal antibodies are deemed more potent than their monoclonal counterparts as they target more than one tumor antigen on the cells, thereby hindering the progression of cancer. For instance, the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a voluntary health organization in the US, predicts that there will be roughly 609,820 deaths related to cancer in the USA by 2023. As such, the escalating incidence of chronic diseases, cancer included, is predicted to boost the demand for bi-specific monoclonal antibodies for effective treatment._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp_x000D_

_x000D_

#What Are the Leading Segments in the Global Bi-Specific MAbS Industry?#_x000D_

The bi-specific MAbS market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab_x000D_

2) By Product Type: In Vivo, In Vitro_x000D_

3) By Indication: Cancer, Haemophilia A, Ophthalmic_x000D_

4) By End Use: Hospitals, Research Institutes, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3_x000D_

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3_x000D_

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)_x000D_

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X_x000D_

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET_x000D_

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A_x000D_

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3_x000D_

_x000D_

#What Are the Key Market Trends in the Bi-Specific MAbS Industry?#_x000D_

Businesses in the bi-specific MAbs sector are demonstrating a growing trend of investing in strategic initiatives such as collaborations and partnerships to broaden their product offerings and increase their global reach. A strategic collaboration is essentially a cooperative alliance between multiple organizations intending to accomplish shared objectives or goals. An example of this occurred in October 2022, when Gilead Sciences, a US-based biopharmaceutical firm, and MacroGenics, another US-based biopharmaceutical company, formed an exclusive partnership to progress the development of MGD024, a bispecific antibody aimed at CD123 and CD3, leveraged by MacroGenics’ DART platform, in addition to two other bispecific research programs. This partnership provides Gilead an exclusive option to license MGD024, which could potentially serve as a treatment for several hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 has been created to reduce cytokine-release syndrome (CRS) and moderate the dosing regimen, which could potentially lead to improved treatment experiences for patients and better clinical outcomes for individuals diagnosed with AML and MDS._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report_x000D_

_x000D_

#What Is the Regional Outlook for the Bi-Specific MAbS Market?#_x000D_

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the bi-specific mabs market, and how is it changing globally?_x000D_

2. Who are the major companies in the bi-specific mabs market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the bi-specific mabs market right now?_x000D_

4. Which products or customer segments are growing the most in the bi-specific mabs market?_x000D_

5. What factors are helping or slowing down the growth of the bi-specific mabs market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model